1. Home
  2. HRTG vs CGEM Comparison

HRTG vs CGEM Comparison

Compare HRTG & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heritage Insurance Holdings Inc.

HRTG

Heritage Insurance Holdings Inc.

HOLD

Current Price

$21.56

Market Cap

704.5M

Sector

Finance

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$16.13

Market Cap

904.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HRTG
CGEM
Founded
2012
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
704.5M
904.7M
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
HRTG
CGEM
Price
$21.56
$16.13
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
8
Target Price
$33.50
$30.13
AVG Volume (30 Days)
467.6K
956.5K
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
214.43
N/A
EPS
1.19
N/A
Revenue
$847,330,000.00
N/A
Revenue This Year
$7.50
N/A
Revenue Next Year
$6.74
$5.20
P/E Ratio
$18.48
N/A
Revenue Growth
3.71
N/A
52 Week Low
$16.83
$5.68
52 Week High
$31.98
$16.74

Technical Indicators

Market Signals
Indicator
HRTG
CGEM
Relative Strength Index (RSI) 32.08 62.01
Support Level $20.98 $11.92
Resistance Level $24.26 N/A
Average True Range (ATR) 1.07 1.03
MACD -0.17 0.08
Stochastic Oscillator 3.12 89.05

Price Performance

Historical Comparison
HRTG
CGEM

About HRTG Heritage Insurance Holdings Inc.

Heritage Insurance Holdings Inc is a regional property and casualty insurance company that offers a variety of personal and commercial insurance products. Through its subsidiaries, Heritage Property & Casualty Insurance, Narragansett Bay Insurance, and Zephyr Insurance, the company issues personal residential property insurance across various states in the U.S. It also offers commercial residential insurance predominantly for its Florida properties. Heritage Insurance manages insurance underwriting, customer services, actuarial analysis, distribution, and claims processing internally. The company operates in Alabama, California, Connecticut, Delaware, Florida, Georgia, Hawaii, Maryland, Massachusetts, Mississippi, New Jersey, New York, North Carolina, Rhode Island, and South Carolina.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: